Open trial of nefazodone for combat-related posttraumatic stress disorder.

Journal Article (Clinical Trial;Journal Article)

BACKGROUND: Because of its ability to block 5-HT2 receptors postsynaptically and inhibit 5-HT reuptake presynaptically and/or its enhancement of sleep quality, nefazodone may be useful for symptom management in posttraumatic stress disorder (PTSD) patients. METHOD: Ten patients with combat-related DSM-IV posttraumatic stress disorder (PTSD) entered an open-label 12-week trial of nefazodone with a 4-week follow-up, beginning with 100 mg/day and increasing as necessary to achieve a maximal response or until reaching a maximum dosage of 600 mg/day. RESULTS: Nefazodone was well tolerated, and no significant changes in sexual function were reported. Based on Clinical Global Impressions-Improvement scores, all 10 patients were rated as much improved. All PTSD symptoms (except self-reported PTSD reexperiencing symptoms), sleep, and clinician-rated depression significantly improved at week 12. At follow-up, significant changes were maintained, and self-reported PTSD reexperiencing symptoms had also significantly improved. Effect sizes for all changed symptoms were moderate to large at week 12 and at follow-up. Self-reported and clinician-rated anger significantly improved. Self-reported depression failed to improve. Improvement in social and occupational functioning was minimal. CONCLUSION: These preliminary data suggest that nefazodone may be effective in reducing the 3 primary PTSD symptom clusters and may be particularly helpful in improving sleep and decreasing anger.

Full Text

Duke Authors

Cited Authors

  • Hertzberg, MA; Feldman, ME; Beckham, JC; Moore, SD; Davidson, JR

Published Date

  • September 1998

Published In

Volume / Issue

  • 59 / 9

Start / End Page

  • 460 - 464

PubMed ID

  • 9771816

International Standard Serial Number (ISSN)

  • 0160-6689

Digital Object Identifier (DOI)

  • 10.4088/jcp.v59n0904


  • eng

Conference Location

  • United States